The efficacy of pitobrutinib in the treatment of leukemia

Pirtobrutinib, a highly selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor, has demonstrated significant efficacy in the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Its clinical data shows that the overall response rate (ORR) in CLL patients is as high as 73%, and in MCL patients it is 58%, which is an impressive effect.

Pittobrutinib also showed activity in patients who developed resistance to earlier covalent BTK inhibitors. Notably, overall response rates with pitobrutinib remained similar regardless of whether patients had received BTK pretreatment, demonstrating its potential to overcome BTK inhibitor resistance.

In the treatment of CLL, pitobrutinib monotherapy has shown high objective response rates and sustained disease control. This therapeutic effect is achieved because pitobrutinib can accurately inhibit the activity of BTK, thus blocking the B cell receptor signaling pathway and inhibiting the growth and division of lymphoma cells. In addition, pitobrutinib has a good safety and tolerability profile, allowing patients to better tolerate treatment and sustain benefits.

In addition toCLL, pitobrutinib has also shown good efficacy in the treatment of MCL. For those MCL patients who have relapsed or are refractory after multiple treatments, pitobrutinib provides a new treatment option and is expected to prolong patients' survival and improve their quality of life.

In addition, pitobrutinib also showed inhibitory activity against BTK carrying theC481 mutation. This mutation usually renders traditional BTK inhibitors ineffective, but pitobrutinib, through its non-covalent binding mechanism, is able to overcome this problem and bring new treatment hope to patients carrying such mutations.

In general, pitobrutinib, as a new BTK inhibitor, has demonstrated significant efficacy and good safety in the treatment of CLL and MCL. Its potential to overcome resistance to BTK inhibitors and its inhibitory activity against BTKs harboring the C481 mutation make pitobrutinib an important advance in the treatment of lymphoma.

xa0

Reference: https://pubmed.ncbi.nlm.nih.gov/38235739/